新西兰开始为期两年的基因组学试点,通过在当地处理测试来减少癌症和罕见疾病的检查延迟. New Zealand begins two-year genomics pilot to cut cancer and rare disease test delays by processing tests locally.

新西兰已经启动为期两年的试点项目, 以在国内进行癌症和罕见疾病的基因组测试,减少对海外实验室的依赖. New Zealand has launched a two-year pilot to bring genomic testing for cancer and rare disorders home, reducing reliance on overseas labs. 由新西兰卫生部领导,由Illumina支持的这一计划将使用全基因组和综合性基因分析处理超过6,000个样本,旨在将目前出口的一半测试转移到当地. The initiative, led by Health New Zealand and supported by Illumina, will process over 6,000 samples using whole genome and comprehensive genomic profiling, aiming to shift half of currently exported tests locally. 它针对的是代谢,结合组织,眼睛,听力和脏疾病等病症, 癌症的应用仍在确定. It targets conditions like metabolic, connective tissue, eye, hearing, and kidney disorders, with cancer applications still being defined. 计划旨在减少患者等待时间,提高诊断准确度,建立当地专业知识,并在五年内节省约500万美元. The program seeks to cut patient wait times, improve diagnostic accuracy, build local expertise, and save about $5 million over five years. 评估工作人员的准备,运作和数据安全性以为未来的国家基因组学服务提供信息. It also evaluates workforce readiness, operations, and data security to inform a future national genomics service. 发行与罕见疾病月相吻合, 强调及时诊断的重要性. The launch coincides with Rare Disorders Month, highlighting the importance of timely diagnosis.